Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Georg Beyer

Showing results (81-90 of 98) with videos related to

Pageof 10
Sort By:
JCI Insight|April 19, 2022
Epigenetic drug screening defines a PRMT5 inhibitor-sensitive pancreatic cancer subtypeFelix Orben, Katharina Lankes, Christian Schneeweis, et al.
Targeted Oncology|February 28, 2023
Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunich<sup>LMU</sup> Molecular Tumor BoardKlara Dorman, Danmei Zhang, Kathrin Heinrich, et al.
Journal of Cancer Research and Clinical Oncology|October 1, 2024
Trametinib in combination with hydroxychloroquine or palbociclib in advanced metastatic pancreatic cancer: data from a retrospective, multicentric cohort (AIO AIO-TF/PAK-0123)David Witte, Ina Pretzell, Timm M Reissig, et al.
Gastroenterology|July 23, 2022
Independent Validation and Assay Standardization of Improved Metabolic Biomarker Signature to Differentiate Pancreatic Ductal Adenocarcinoma From Chronic PancreatitisUjjwal M Mahajan, Bettina Oehrle, Simon Sirtl, et al.
Gastroenterology|May 8, 2026
Neutrophil-Driven Trogocytosis in PDAC Liver Metastases Restrains Immunosuppressive Macrophage Polarization and Limits Metastatic ProgressionLarissa Belz, Dominic van den Heuvel, Badr Kilani, et al.
Gastroenterology|August 10, 2018
Immune Cell and Stromal Signature Associated With Progression-Free Survival of Patients With Resected Pancreatic Ductal AdenocarcinomaUjjwal Mukund Mahajan, Eno Langhoff, Elisabetta Goni, et al.
JNCI Cancer Spectrum|April 17, 2020
Cathepsin D Expression and Gemcitabine Resistance in Pancreatic CancerUjjwal M Mahajan, Elisabetta Goni, Enno Langhoff, et al.
Gut|December 21, 2023
Gut microbiota predicts severity and reveals novel metabolic signatures in acute pancreatitisChristoph Ammer-Herrmenau, Kai L Antweiler, Thomas Asendorf, et al.
Targeted Oncology|August 18, 2023
A Retrospective Analysis of Biliary Tract Cancer Patients Presented to the Molecular Tumor Board at the Comprehensive Cancer Center MunichDanmei Zhang, Klara Dorman, Kathrin Heinrich, et al.
The Lancet. Gastroenterology & Hepatology|May 19, 2025
Validation of two plasma multimetabolite signatures for patients at risk of or with suspected pancreatic ductal adenocarcinoma (METAPAC): a prospective, multicentre, investigator-masked, enrichment design, phase 4 diagnostic studyUjjwal M Mahajan, Bettina Oehrle, Elisabetta Goni, et al.
Pageof 10

Showing results (81-90 of 98) with videos related to

Sort By:
Pageof 10
JCI Insight|April 19, 2022
Epigenetic drug screening defines a PRMT5 inhibitor-sensitive pancreatic cancer subtypeFelix Orben, Katharina Lankes, Christian Schneeweis, et al.
Targeted Oncology|February 28, 2023
Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunich<sup>LMU</sup> Molecular Tumor BoardKlara Dorman, Danmei Zhang, Kathrin Heinrich, et al.
Journal of Cancer Research and Clinical Oncology|October 1, 2024
Trametinib in combination with hydroxychloroquine or palbociclib in advanced metastatic pancreatic cancer: data from a retrospective, multicentric cohort (AIO AIO-TF/PAK-0123)David Witte, Ina Pretzell, Timm M Reissig, et al.
Gastroenterology|July 23, 2022
Independent Validation and Assay Standardization of Improved Metabolic Biomarker Signature to Differentiate Pancreatic Ductal Adenocarcinoma From Chronic PancreatitisUjjwal M Mahajan, Bettina Oehrle, Simon Sirtl, et al.
Gastroenterology|May 8, 2026
Neutrophil-Driven Trogocytosis in PDAC Liver Metastases Restrains Immunosuppressive Macrophage Polarization and Limits Metastatic ProgressionLarissa Belz, Dominic van den Heuvel, Badr Kilani, et al.
Gastroenterology|August 10, 2018
Immune Cell and Stromal Signature Associated With Progression-Free Survival of Patients With Resected Pancreatic Ductal AdenocarcinomaUjjwal Mukund Mahajan, Eno Langhoff, Elisabetta Goni, et al.
JNCI Cancer Spectrum|April 17, 2020
Cathepsin D Expression and Gemcitabine Resistance in Pancreatic CancerUjjwal M Mahajan, Elisabetta Goni, Enno Langhoff, et al.
Gut|December 21, 2023
Gut microbiota predicts severity and reveals novel metabolic signatures in acute pancreatitisChristoph Ammer-Herrmenau, Kai L Antweiler, Thomas Asendorf, et al.
Targeted Oncology|August 18, 2023
A Retrospective Analysis of Biliary Tract Cancer Patients Presented to the Molecular Tumor Board at the Comprehensive Cancer Center MunichDanmei Zhang, Klara Dorman, Kathrin Heinrich, et al.
The Lancet. Gastroenterology & Hepatology|May 19, 2025
Validation of two plasma multimetabolite signatures for patients at risk of or with suspected pancreatic ductal adenocarcinoma (METAPAC): a prospective, multicentre, investigator-masked, enrichment design, phase 4 diagnostic studyUjjwal M Mahajan, Bettina Oehrle, Elisabetta Goni, et al.
Pageof 10